Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research Institute
Epalinges, Switzerland, 29 September 2014
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.
|Media Name||Media Type||Description||Download|
|140929 Mymetics - Texas Biomed Release for Gates funding- Final For Distribution||Download|